Insider Selling: Arvinas (NASDAQ:ARVN) Director Sells $466,273.37 in Stock

Arvinas, Inc. (NASDAQ:ARVN) Director John Houston sold 35,297 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $13.21, for a total value of $466,273.37. Following the completion of the sale, the director directly owned 1,122,183 shares of the company’s stock, valued at approximately $14,824,037.43. This trade represents a 3.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Arvinas Trading Up 3.0%

NASDAQ:ARVN opened at $13.76 on Thursday. The business’s fifty day moving average price is $12.56 and its 200 day moving average price is $10.76. The firm has a market capitalization of $880.09 million, a price-to-earnings ratio of -10.75 and a beta of 1.87. Arvinas, Inc. has a 1-year low of $5.90 and a 1-year high of $18.93.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.55). The business had revenue of $9.50 million for the quarter, compared to analyst estimates of $37.26 million. Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The company’s revenue was down 84.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.63) earnings per share. Equities analysts forecast that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Institutional Trading of Arvinas

A number of institutional investors and hedge funds have recently made changes to their positions in ARVN. Invesco Ltd. boosted its stake in shares of Arvinas by 26.9% during the 4th quarter. Invesco Ltd. now owns 302,100 shares of the company’s stock worth $3,583,000 after acquiring an additional 64,044 shares in the last quarter. Corient Private Wealth LLC bought a new stake in Arvinas during the fourth quarter worth approximately $127,000. State of Tennessee Department of Treasury acquired a new position in Arvinas during the fourth quarter valued at approximately $323,000. Ikarian Capital LLC raised its position in shares of Arvinas by 58.3% in the fourth quarter. Ikarian Capital LLC now owns 358,257 shares of the company’s stock valued at $4,249,000 after purchasing an additional 132,000 shares during the period. Finally, Voloridge Investment Management LLC acquired a new stake in shares of Arvinas in the fourth quarter worth $1,079,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ARVN shares. Citigroup upgraded shares of Arvinas from a “neutral” rating to a “buy” rating and upped their price objective for the company from $10.00 to $15.00 in a research note on Tuesday, January 6th. Stephens increased their price objective on Arvinas from $14.00 to $15.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Wall Street Zen downgraded Arvinas from a “hold” rating to a “sell” rating in a research note on Monday. Wells Fargo & Company dropped their target price on Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Finally, Barclays lifted their price target on Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Ten research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Arvinas presently has a consensus rating of “Hold” and an average target price of $13.47.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.